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Tumors frequently alter antigen processing and presenta-
tion by major histocompatibility complex (MHC) proteins
in order to evade recognition by the immune system.
CD1d, a non-polymorphic MHC class I-like molecule, pre-
sents lipid antigens to Natural killer T (NKT) cells, which
have potent anti-tumor effector functions. NKT cells are
able to directly lyse malignant cells and induce anti-tumor
responses by modulating other immune cells. Many hema-
tologic malignancies express CD1d and the co-stimulatory
proteins needed to induce anti-tumor responses by NKT
cells, yet most tumors are poorly immunogenic. Here we
sought to test the hypothesis that B cell lymphomas use
epigenetic mechanisms to dysregulate CD1d-mediated
antigen processing and presentation leading to a func-
tional impairment in the ability of NKT cells to recognize
tumors. To assess the functional outcomes of epigenetic
modulation, murine and human B cell lymphomas were
pretreated with HDAC inhibitors and then we assessed
their ability to process and present antigen. Pretreatment
with Trichostatin A (TSA) resulted in a dose-dependent
increase in CD1d-mediated NKT cell activation by lym-
phoma cells without altering CD1d or co-stimulatory
molecule cell surface expression. Similarly, pretreatment
with TSA enhanced MHC class II mediated antigen pre-
sentation to CD4+ T cells. In contrast, treatment with the
more selective HDACi, MC1568, resulted in an increase in
CD1d-mediated NKT cell activation, but did not enhance
antigen presentation by HLA-DR4. These data indicate
that HDACi differentially modulate CD1d and MHC class
II-mediated antigen presentation and suggests a role for
multiple HDACs in regulating antigen processing and pre-
sentation. Overall, our studies demonstrate the efficacy of
HDACi in restoring NKT cell mediated anti-tumor
responses and may provide the basis for an NKT cell-
based immunotherapeutic strategy that not only enhances
the immune response, but also increases the immunogeni-
city of the tumor itself.
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